PIGMENTATION DISORDERS TREATMENT MARKET ANALYSIS

Pigmentation Disorders Treatment Market, By Disorder Type (Melasma, Vitiligo, Albinism, Post-Inflammatory Hyperpigmentation (PIH), and Others), By Drug Type (Corticosteroids, Calcineurin Inhibitors, Janus kinase inhibitor, Melanin Synthesis Inhibitor, and Others), By Route of Administration (Oral, Topical, and Other), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Apr 2024
Code : CMI5421
Pages :172
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges – Lack of Reimbursement Policies

Lack of reimbursement policies is expected to hinder growth of the global pigmentation disorders treatment market. For instance, reimbursement is provided for medical expenses and treatment, but in the case of pigmentation disorders and its treatments, it is not covered under any policy. Insurance companies rarely cover these procedures, owing to which the patient has to pay out of pocket. The lack of reimbursement policies poses a challenge to the market.

Market Opportunities – Rise in Demand for Safe and Effective Treatment

Rise in demand for safe & effective treatment is expected to offer significant growth opportunities for players in the pigmentation disorders treatment market. For instance, in May 2022, CLINUVEL PHARMACEUTICALS LTD, a pharmaceutical company, announced that a new potential therapy for pigment loss disorder vitiligo will undergo further studies in North America. The drug afamelanotide, approved by the U.S. and European regulators for a rare light intolerance disorder, is being evaluated by CLINUVEL PHARMACEUTICALS LTD as a treatment for vitiligo patients with darker skin types.